Skip to main content

Table 4 Base-case analysis results

From: The cost-effectiveness analysis of newborn screening for inherited metabolic disorders in China using tandem mass spectrometry: a real-world evidence

Item

Screening group

non-screening group

Increment

(screening vs. non screening)

Total cost (CNY)

1,000,452

157,303

843,148

 Screening costs

924,134

0

924,134

 Diagnosis costs

45,861

3,705

42,156

 Treatment costs

30,456

153,598

-123,142

QALYs

16.47

3.97

12.51

ICER(CNY/QALY)

67,417